Search

Displaying results 2421 - 2430 of 8009 in total
  1. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]

  2. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836] … Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class.

  3. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    It is available in topical formulations for the treatment of skin infections such as athlete's foot.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  7. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    [L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair

  8. Indication

    Lymphoblastic Lymphoma

    go.drugbank.com/conditions/DBCOND0032667
    Drugs: Asparaginase Erwinia chrysanthemi · Mercaptopurine
    Synonyms: Non-Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype
  9. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. … Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation.